This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F.Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis and Rheumatism 58: 939-946, No. 4, Apr 2008
Rights and permissions
About this article
Cite this article
Etanercept, adalimumab worth trying over infliximab for RA. Pharmacoecon. Outcomes News 554, 6 (2008). https://doi.org/10.2165/00151234-200805540-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805540-00013